Regeneron Secures $270 Million U.S. Contract Extension for Ebola Treatment Inmazeb

Regeneron presented Phase III data for Libtayo (cemiplimab) in skin cancer, showing a 37% reduction in death risk. Pfizer's STARBOARD trial showed Keytruda triplet therapy improved outcomes in melanoma. Both studies were discussed at ESMO 2026.

Regeneron Pharmaceuticals extended a $270m contract with the US Government to supply its Ebola therapy, Inmazeb, through 2031. The deal builds on a 2020 partnership with BARDA to maintain national emergency stockpiles. Inmazeb, approved by the FDA in 2020, has shown a 55% mortality reduction in clinical trials. Separately, Regeneron is testing a monotherapy derived from Inmazeb in the DRC.

Regeneron Pharmaceuticals extended its agreement with BARDA to supply additional Inmazeb doses for U.S. Ebola preparedness, adding $270 million in value. The deal expands a 2020 procurement agreement and runs through 2031.

Regeneron (REGN) reports Q3 earnings on Oct. 30, with full Dupixent profit inclusion for the first time. Q2 revenue was $4.29B, up 16.73%, with Dupixent sales at $6B. Analysts expect Q3 EPS of $16.20 and revenue of $4.56B. Collaboration margins and Eylea HD performance are key focuses.

Regeneron extended its agreement with BARDA by $270 million to supply additional doses of Inmazeb, an FDA-approved Ebola treatment, through 2031. The company is also advancing maftivimab in clinical trials for Bundibugyo virus disease, following promising lab and animal studies.

Regeneron (REGN) extended its agreement with BARDA to supply additional doses of its Ebola treatment, Inmazeb, through 2031. The deal is worth approximately $270 million. Inmazeb has shown a 55% mortality reduction in clinical studies. REGN stock closed at $805.02, down 1.72%.